Open AccessP492: TAMIBAROTENE IN COMBINATION WITH VENETOCLAX AND AZACITIDINE IN PREVIOUSLY UNTREATED ADULT PATIENTS SELECTED FOR RARA‐POSITIVE AML WHO ARE INELIGIBLE FOR STANDARD INDUCTION THERAPY (SELECT AML‐1)
Author(s) -
Stein E.,
Botton S.,
Pigneux A.,
McMahon C.,
Ball B.,
Borthakur G.,
Eghtedar A.,
Kambhampati S.,
Tache J.,
Wang E.,
Kelley H.,
Volkert A.,
Baker K.,
KangFortner Q.,
Hodgson G.,
Madigan C.,
Warlick E.,
Roth D.,
Kelly M.,
Pollyea D.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000844856.73683.5f
Subject(s) - venetoclax , medicine , azacitidine , oncology , ven , leukemia , chemistry , computer science , dna methylation , gene expression , computer security , chronic lymphocytic leukemia , gene , biochemistry